Released Dec 4, 2020, after the close
10-Q filed Dec 4, 2020, 65 days after period end · 0001193125-20-310715
Q3 2020 · 10-Q
Revenue$179.00K$179.00K no prior Q3 2019 on fileno prior Q2 2020 on file
Net Income-$18.37M-$18.37M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$3.12-$3.12 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$18,489,000N/M
Operating Cash Flowderived$2,726,000—
Free Cash Flowderived-$2,699,000—
Margins · derived
Operating margin-10329.1%
Net margin-10260.9%
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 |
|---|---|---|
| Revenue | $179.00K | — |
| Net Income | -$18.37M | -$13.09M |
| EPS Diluted | -$3.12 | -$3.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR